Compare Biogen Inc (BIIB) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs General Dynamics Corporation — how do they compare? Biogen Inc trades at $205.59 (market cap $30.13B), while General Dynamics Corporation trades at $391.15 (market cap $106.03B). The key difference: General Dynamics Corporation is far larger — about 3.5× Biogen Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GD | |
|---|---|---|
Market Cap | $30.13B | $106.03B |
Sector | Health | Industrials |
52-Week High | $216.63 | $395.97 |
52-Week Low | $128.93 | $312.53 |
Enterprise Value | $37.20B | $111.17B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
General Dynamics (GD) trades at $395.97, up 1.0% on the day, near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats, including Q2 2026 EPS of $4.24 versus $3.96 expected. Revenue growth is robust, with 2025 revenue at $52.55 billion, and the company secured a major $76.6 billion Navy contract in July 2026, boosting its backlog.
Outlook remains positive driven by defense budget tailwinds and strong contract wins, but valuation multiples like a P/E of 23.9 suggest limited upside from current levels. Risks include execution on large contracts and macroeconomic pressures on government spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
